Inflammatory breast cancer management in the National Comprehensive Cancer Network: The disease, recurrence pattern, and outcome

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages 1-7

  Matro, Jennifer M ^a   Li, Tianyu ^a   Cristofanilli, Massimo ^b   Hughes, Melissa E ^c   Ottesen, Rebecca A ^d   Weeks, Jane C ^c   Wong, Yu Ning ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Brain metastases; Inflammatory breast cancer; Metastatic breast cancer; Multimodality therapy; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CLINICAL FEATURE; FEMALE; HUMAN; INFLAMMATORY BREAST CANCER; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL TIME; COMMUNITY CARE; FOLLOW UP; HEALTH CARE; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMMUNITY NETWORKS; COMPREHENSIVE HEALTH CARE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84920404524     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.05.005     Document Type: Article

References (36)

1. K.W. Hance, W.F. Anderson, S.S. Devesa, H.A. Young, and P.H. Levine Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst 97 2005 966 975
2. P.H. Levine, S.C. Steinhorn, L.G. Ries, and J.L. Aron Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program J Natl Cancer Inst 74 1985 291 297
3. F.M. Robertson, M. Bondy, and W. Yang Inflammatory breast cancer: the disease, the biology, the treatment CA Cancer J Clin 60 2010 351 375
4. P.A. Wingo, P.M. Jamison, J.L. Young, and P. Gargiullo Population-based statistics for women diagnosed with inflammatory breast cancer (United States) Cancer Causes Control 15 2004 321 328
5. M. Cristofanilli, V. Valero, and A.U. Buzdar Inflammatory breast cancer (IBC) and patterns of recurrence Cancer 110 2007 1436 1444
6. J.A. Low, A.W. Berman, S.M. Steinberg, D.N. Danforth, M.E. Lippman, and S.M. Swain Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy J Clin Oncol 22 2004 4067 4074
7. F. Bertucci, C. Tarpin, and E. Charafe-Jauffret Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment Bone Marrow Transplant 33 2004 913 920
8. C.K. Christian, J. Niland, and S.B. Edge A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network Ann Surg 243 2006 241
9. J. Weeks Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network Oncology (Williston Park) 13 1999 69
10. J. Weeks Outcomes assessment in the NCCN Oncology (Williston Park) 11 1997 137
11. S. Dawood, N. Ueno, and V. Valero Identifying factors that impact survival among women with inflammatory breast cancer Ann Oncol 23 2012 870 875
12. M.A. Owens, B.C. Horten, and M.M. Da Silva HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 2004 63 69
13. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
14. J.M. Walshe, and S.M. Swain Clinical aspects of inflammatory breast cancer Breast Dis 22 2006 35 44
15. I. Van der Auwera, G.G. Van den Eynden, and C.G. Colpaert Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study Clin Cancer Res 11 2005 7637 7642
16. E. Baldini, G. Gardin, G. Evangelista, T. Prochilo, P. Collecchi, and R. Lionetto Long-term results of combined-modality therapy for inflammatory breast carcinoma Clin Breast Cancer 5 2004 358 363
17. S. Rehman, C.A. Reddy, and R.D. Tendulkar Modern outcomes of inflammatory breast cancer Int J Radiat Oncol Biol Phys 84 2012 619 624
18. A. Distefano, H.Y. Yap, G.N. Hortobagyi, and G.R. Blumenschein The natural history of breast cancer patients with brain metastases Cancer 44 1979 1913 1918
19. W. Boogerd, V. Vos, A. Hart, and G. Baris Brain metastases in breast cancer; natural history, prognostic factors and outcome J Neurooncol 15 1993 165 174
20. D. Crivellari, O. Pagani, and A. Veronesi High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel Ann Oncol 12 2001 353 356
21. J.F. Stewart, R.J. King, S.A. Sexton, R.R. Millis, R.D. Rubens, and J.L. Hayward Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer Eur J Cancer 17 1981 449 453
22. G.M. Clark, G. Sledge, C.K. Osborne, and W. McGuire Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients J Clin Oncol 5 1987 55 61
23. A.M. Gonzalez-Angulo, M. Cristofanilli, and E.A. Strom Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment Cancer 101 2004 1760 1766
24. E. Lim, and N.U. Lin New insights and emerging therapies for breast cancer brain metastases Oncology 26 2012 652 659
25. H. Kennecke, R. Yerushalmi, and R. Woods Metastatic behavior of breast cancer subtypes J Clin Oncol 28 2010 3271 3277
26. N.U. Lin, E. Claus, J. Sohl, A.R. Razzak, A. Arnaout, and E.P. Winer Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer Cancer 113 2008 2638 2645
27. A.M. Brufsky, M. Mayer, and H.S. Rugo Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER Clin Cancer Res 17 2011 4834 4843
28. J.C. Bendell, S.M. Domchek, and H.J. Burstein Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2003 2972 2977
29. H.-J. Stemmler, M. Schmitt, A. Willems, H. Bernhard, N. Harbeck, and V. Heinemann Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anticancer Drugs 18 2007 23 28
30. G. Somlo, S.K. Lau, and P. Frankel Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology Breast Cancer Res Treat 128 2011 155 163
31. M. Cristofanilli, G.T. Budd, and M.J. Ellis Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 2004 781 791
32. M. Mehta The dandelion effect: treat the whole lawn or weed selectively? J Clin Oncol 29 2011 121 124
33. W.D. Foulkes, I.E. Smith, and J.S. Reis-Filho Triple-negative breast cancer N Engl J Med 363 2010 1938 1948
34. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
35. S. Dawood Triple-negative breast cancer: epidemiology and management options Drugs 70 2010 2247 2258
36. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712